Saturday, February 7, 2026
StockstToday.com Logo
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing
No Result
View All Result
StocksToday.com Logo
No Result
View All Result
Home Breaking News

Goldman Sachs Analyst Maintains Buy Rating for Nutrien with Lowered Price Target

Elaine Mendonca by Elaine Mendonca
February 1, 2024
in Breaking News
0
Finance_Budgeting (1)
0
SHARES
10
VIEWS
Share on FacebookShare on Twitter

On February 1, 2024, Adam Samuelson, an analyst at Goldman Sachs, reaffirmed his positive sentiment towards Nutrien (NTR) by maintaining a Buy rating. However, he did make an adjustment to the price target, lowering it from $88 to $78. This adjustment aligns with the median target of $75.00 suggested by a group of 23 analysts.

Although the price target has decreased, the Buy rating still signifies an optimistic outlook for Nutrien’s stock. It is crucial for investors to take into account the diverse range of analyst recommendations and price targets in order to make well-informed investment decisions.

NTR (Nutrien Ltd.) Stock Performance Shows Positive Signs with 2.17% Rise: Potential Undervaluation or Challenges?

On February 1, 2024, the stock performance of NTR (Nutrien Ltd.) showed some positive signs with a 2.17% rise in price since the market last closed. NTR opened at $50.36, which was $0.49 higher than its previous close, indicating some positive sentiment surrounding the stock at the opening of the market. The stock was trading near the bottom of its 52-week range, suggesting potential undervaluation or challenges. Investors and analysts would have closely monitored NTR’s stock throughout the day to assess its future performance.

NTR Stock Performance on February 1, 2024: Mixed Results with Strong Revenue Growth but Decline in Net Income and EPS

NTR Stock Performance on February 1, 2024:

Total Revenue:
– NTR reported a total revenue of $37.88 billion over the past year, a 36.71% increase compared to the previous year.
– However, when compared to the previous quarter’s figure of $5.63 billion, there was a significant decline of 51.68%.

Net Income:
– NTR reported a net income of $7.66 billion over the past year, a substantial increase of 142.94%.
– The net income for the most recent quarter, Q3, stood at $75.00 million, indicating a decline of 82.95% compared to the previous quarter.

Earnings per Share:
– NTR’s EPS over the past year was reported at $14.18, a significant increase of 157.01%.
– The EPS for the most recent quarter, Q3, was reported at $0.15, representing a decline of 82.92% compared to the previous quarter.

Overall, NTR’s stock performance on February 1, 2024, showcased a mixed picture. While the company experienced substantial growth in total revenue, net income, and EPS over the past year, the most recent quarter’s figures indicated a decline across these key financial metrics. Investors should carefully analyze the reasons behind the decline before making investment decisions.

Tags: NTR
Elaine Mendonca

Elaine Mendonca

Related Posts

NFT projects
Breaking News

The Impact of TikToks Fate on USChina Relations and American Tech Giants

March 16, 2024
Businesses finance
Breaking News

Blackstone Strategic Credit 2027 Term Fund BGB Announces Monthly Dividend of 93 Cents per Share

March 15, 2024
Healthcare-sector
Breaking News

Analyzing Short Interest in Molina Healthcare Inc MOH

March 15, 2024
Next Post
Real Estate Investment Markets and money

Analyst Maintains Positive Outlook on DR Horton with Revised Price Target

Corbus Pharmaceuticals Raises Funds for Clinical Development and Faces Market Fluctuations

Diana Shipping Inc Secures Major Time Charter Contract with Nippon Yusen Kabushiki Kaisha

Recommended

Super Micro Computer Stock

Super Micro Stock Surges Amid AI Infrastructure Boom

4 months ago
Adobe Stock

Adobe’s AI Ambitions Face Investor Skepticism

4 months ago
IBM Stock

Strong IBM Earnings Fail to Impress Market as Key Segment Shows Weakness

4 months ago
Inozyme Pharma Inc Stock

Inozyme Pharma Acquisition Finalized: Strategic Focus Shifts to Clinical Development

5 months ago

Categories

  • AI & Quantum Computing
  • Analysis
  • Analyst Ratings
  • Asian Markets
  • Automotive & E-Mobility
  • Banking & Insurance
  • Bitcoin
  • Blockchain
  • Bonds
  • Breaking News
  • Business & Industry Trends
  • Cannabis
  • Chemicals
  • Commodities
  • Consumer & Luxury
  • Crypto Stocks
  • Cryptocurrency
  • Cyber Security
  • DAX
  • Defense & Aerospace
  • Dividends
  • Dow Jones
  • E-Commerce
  • Earnings
  • Emerging Markets
  • Energy & Oil
  • ETF
  • Ethereum & Altcoins
  • European Markets
  • Forex
  • Gaming & Metaverse
  • Gold & Precious Metals
  • Healthcare
  • Hydrogen
  • Index
  • Industrial
  • Insider Trading
  • IPOs
  • Market Commentary
  • Market News
  • MDAX & SDAX
  • Mergers & Acquisitions
  • Nasdaq
  • Newsletter
  • Penny Stocks
  • Pharma & Biotech
  • Real Estate & REITs
  • Renewable Energy
  • S&P 500
  • Semiconductors
  • Space
  • Stock Picks
  • Stock Targets
  • Stocks
  • TecDAX
  • Tech & Software
  • Telecommunications
  • Trading & Momentum
  • Turnaround
  • Uncategorized
  • Value & Growth

Topics

Adobe Alibaba Alphabet Amazon AMD Apple ASML BioNTech Bitcoin Broadcom Coca-Cola Coinbase D-Wave Quantum Eli Lilly Fiserv IBM Intel Kraft Heinz Marvell Technology META Micron Microsoft MP Materials MSCI World ETF Newmont Mining NIO Novo Nordisk Nvidia Ocugen Opendoor Oracle Palantir PayPal Plug Power QuantumScape Robinhood Rocket Lab USA Strategy Super Micro Computer Synopsys Tesla Tilray Unitedhealth Uranium Energy Viking Therapeutics
No Result
View All Result

Highlights

Myers Industries Set to Report Full-Year and Q4 2025 Results

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

Riley Exploration Permian Bolsters Board with Industry Veteran Amid Shareholder Activity

Great Lakes Dredge & Dock: A Cash Flow Inflection Point Approaches

Investors Await March Report for Boston Omaha’s Strategic Direction

Universal Insurance Maintains Quarterly Payout Amid Sector Headwinds

Trending

Orthofix Medical Stock
Earnings

Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio

by Rodolfo Hanigan
February 7, 2026
0

Investor attention turns to Orthofix Medical as the company bolsters the clinical support for its biologics business...

CrossFirst Bankshares Stock

A New Chapter for First Busey as CrossFirst Merger Finalizes

February 7, 2026
Golden Entertainment Stock

Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

February 7, 2026
Myers Industries Stock

Myers Industries Set to Report Full-Year and Q4 2025 Results

February 7, 2026
OneSpan Stock

OneSpan Strengthens Mobile Security Arsenal with Strategic Acquisition

February 7, 2026

StocksToday.com is your one-stop destination for the latest stock news and analysis. We provide in-depth coverage of the stock market, including market news, company news, sector news, IPO news, investment strategies, personal finance, international markets, and more.

Follow us on social media:

Recent News

  • Orthofix Medical Strengthens Scientific Foundation for Biologics Portfolio
  • A New Chapter for First Busey as CrossFirst Merger Finalizes
  • Golden Entertainment to Exit Public Markets in Strategic Privatization Deal

Category

  • About
  • Advertise
  • Careers
  • Contact
  • Imprint
  • Privacy Policy
  • Terms of Service

© 2023 StocksToday.com

No Result
View All Result
  • Home
  • Tech & Software
  • Earnings
  • Analysis
  • Trading & Momentum
  • Cryptocurrency
  • Banking & Insurance
  • AI & Quantum Computing

© 2023 StocksToday.com